Xinghai Li

Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Journal: Signal transduction and targeted therapy

Published: June 10, 2025

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity.

Journal: Investigational new drugs

Published: January 23, 2025

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal: Clinical pharmacology in drug development

Published: June 14, 2024

A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.

A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia.

Journal: Scientific reports

Published: October 17, 2023

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia.

Journal: Clinical drug investigation

Published: May 07, 2023

HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells.

HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells.

Journal: Molecular biology reports

Published: March 18, 2022

Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.

Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study.

Journal: The Journal of clinical endocrinology and metabolism

Published: November 10, 2021

Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.

Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.

Journal: International journal of cancer

Published: December 09, 2020

Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.

Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.

Journal: Biochemical pharmacology

Published: December 20, 2019

Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.

Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.

Journal: European journal of medicinal chemistry

Published: June 25, 2019

Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.

Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.

Journal: European journal of medicinal chemistry

Published: December 29, 2018

Synthesis and evaluation of sulfonamide derivatives as potent Human Uric Acid Transporter 1 (hURAT1) inhibitors.

Synthesis and evaluation of sulfonamide derivatives as potent Human Uric Acid Transporter 1 (hURAT1) inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 13, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026